Relmada Therapeutics Inc (nasdaq:RLMD) Share Price

Company Profile

Business description
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Contact
2222 Ponce de Leon Boulevard
Floor 3
Coral GablesFL33134
USA
T: +1 786 629-1376
E: [email protected]
https://www.relmada.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,936.90	12.50	-0.14%
CAC 40	8,141.92	15.90	-0.19%
DAX 40	24,083.53	45.45	-0.19%
Dow JONES (US)	49,167.79	62.92	-0.13%
FTSE 100	10,321.09	57.99	-0.56%
HKSE	25,703.77	221.88	-0.86%
NASDAQ	24,887.10	50.50	0.20%
Nikkei 225	59,937.88	599.48	-0.99%
NZX 50 Index	12,764.40	110.54	-0.86%
S&P 500	7,173.91	8.83	0.12%
S&P/ASX 200	8,712.90	8.30	-0.10%
SSE Composite Index	4,078.78	7.56	-0.19%